Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

OX640 is Orexo’s nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX® The American Academy of Allergy, Asthma & Immunology (AAAAI) is the largest professional…